Ignite Creation Date:
2024-05-06 @ 3:15 PM
Last Modification Date:
2025-12-16 @ 7:16 PM
Study NCT ID:
NCT04576858
Status:
None
Last Update Posted:
2020-10-06 00:00:00
First Post:
2020-01-23 00:00:00
Brief Title:
Clinical Utility of Circulating Tumor DNA in Gastro-Esophageal Cancer
Sponsor:
Rigshospitalet Denmark
Organization:
Rigshospitalet, Denmark
Study Overview
Official Title:
Clinical Utility of Circulating Tumor DNA in Gastro-Esophageal Cancer
Status:
None
Status Verified Date:
2020-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CURE
Brief Summary:
This is a prospective cohort study designed to evaluate the treatment effect as well as predictive and prognostic factors with special emphasis on the clinical utility of ctDNA in plasma in patients with gastroesophageal cancer. Patients with gastroesophageal cancer are included in 5 separate cohorts scheduled for
* Surgical resection + perioperative chemotherapy (cohort 1)
* Neoadjuvant chemoradiotherapy followed by surgical resection (cohort 2)
* Definitive chemoradiotherapy with curative intent (cohort 3)
* Systemic therapy with the intent to prolong survival (cohort 4)
* Palliative treatment without the use of chemotherapy (cohort 5)
* Surgical resection + perioperative chemotherapy (cohort 1)
* Neoadjuvant chemoradiotherapy followed by surgical resection (cohort 2)
* Definitive chemoradiotherapy with curative intent (cohort 3)
* Systemic therapy with the intent to prolong survival (cohort 4)
* Palliative treatment without the use of chemotherapy (cohort 5)
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None